<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04627207</url>
  </required_header>
  <id_info>
    <org_study_id>A70_10BE2006</org_study_id>
    <nct_id>NCT04627207</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of CKD-333 or Co-administration of CKD-333 and D085 in Healthy Volunteers</brief_title>
  <acronym>CKD-333</acronym>
  <official_title>A Randomized, Open, Single-dose, 3 Period Partial Replicated Crossover-design Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Administration of CKD-333 or Co-administration of CKD-330 and D085 in Healthy Volunteers Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical trial to evaluate the safety and pharmacokinetic characteristics of CKD-333 or&#xD;
      Co-administration of CKD-333 and D085 in healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open, single-dose, 3 period partial replicated crossover-design clinical trial&#xD;
      to evaluate the safety and pharmacokinetic characteristics after administration of CKD-333 or&#xD;
      co-administration of CKD-330 and D085 in healthy volunteers under fasting conditions&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of CKD-330, D085, CKD-333</measure>
    <time_frame>Pre-dose (0 hour), post-dose 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
    <description>Area under the CKD-330/D085/CKD-333 concentration in blood-time curve from zero to final</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of CKD-330, D085, CKD-333</measure>
    <time_frame>Pre-dose (0 hour), post-dose 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours</time_frame>
    <description>The maximum CKD-330/D085/CKD-333 concentration in blood sampling time t</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Reference-Reference-Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference-Test-Reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test-Reference-Reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-330 1 Tab. and D085 1 Tab.</intervention_name>
    <description>Other names: Reference</description>
    <arm_group_label>Reference-Reference-Test</arm_group_label>
    <arm_group_label>Reference-Test-Reference</arm_group_label>
    <arm_group_label>Test-Reference-Reference</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-333 1 Tab</intervention_name>
    <description>Other names: Test</description>
    <arm_group_label>Reference-Reference-Test</arm_group_label>
    <arm_group_label>Reference-Test-Reference</arm_group_label>
    <arm_group_label>Test-Reference-Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult volunteers aged 19≤ ~ &lt;55-year-old.&#xD;
&#xD;
          -  Those who have body weight ≥ 55kg (men) or ≥ 45kg (women), with calculated body mass&#xD;
             index(BMI) of 17.5 ≤ ~ &lt; 30.5 kg/m2&#xD;
&#xD;
          -  Those who have no congenital/chronic diseases, abnormal symptoms.&#xD;
&#xD;
          -  Those who were deemed to eligible for participation of clinical trial by laboratory&#xD;
             tests, vital signs and 12-lead ECG etc.&#xD;
&#xD;
          -  Those who voluntarily decide to participate and agree to comply with the cautions and&#xD;
             fully understanding the detailed description of this clinical trial.&#xD;
&#xD;
          -  Those who consent to proper contraception during the study period and do not donate&#xD;
             sperm until 14 days after the last administration of investigational product. And&#xD;
             those who consent not to become pregnant or breastfeeding.&#xD;
&#xD;
          -  Those who have ability and willingness to participate in clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those who have medical history or medical symptom of liver, kidney, nervous system,&#xD;
             respiratory system, digestive system, endocrine system, blood/tumor, urinary system,&#xD;
             cardiovascular system, musculoskeletal disease, or mental disease.&#xD;
&#xD;
          -  Those who have past medical history of gastrointestinal disorder (Crohn's disease,&#xD;
             ulcerative colitis, etc. except simple appendectomy or hernia surgery), which affect&#xD;
             the absorption of drug.&#xD;
&#xD;
          -  Those who have the test results written below,&#xD;
&#xD;
               -  AST or ALT are 2 times higher than upper normal range&#xD;
&#xD;
               -  Creatinine is upper normal range or eGFR (estimated Glomerular Filtration Rate,&#xD;
                  which is calculated by MDRD) &lt; 60 mL/min/1.73m2&#xD;
&#xD;
               -  QTc is higher than 450msec measured by 12-lead ECG&#xD;
&#xD;
               -  CPK is 3 times higher than upper normal range&#xD;
&#xD;
               -  Serum Potassium is higher than 5.5 mEq/L&#xD;
&#xD;
               -  Hematocrit is under normal range&#xD;
&#xD;
          -  Those who exceed alcohol consumption criteria (21 units/week within 3 months) prior to&#xD;
             first administration of investigational product. Or Those who can't quit drinking&#xD;
             alcohol from 48 hours to end of bleeding time point.&#xD;
&#xD;
          -  Those who exceed smoke criteria (20 cigarettes/day within 6 months) prior to first&#xD;
             administration of investigational product. Or Those who can't quit smoking during&#xD;
             hospitalization.&#xD;
&#xD;
          -  Those who have participated in other clinical trial and received Investigational&#xD;
             product within 6 month prior to the first administration of drug.&#xD;
&#xD;
          -  Those who have the test results written below,&#xD;
&#xD;
               -  Systolic blood pressure ≥140 mmHg or &lt;90 mmHg&#xD;
&#xD;
               -  Diastolic blood pressure ≥90 mmHg or &lt;60 mmHg&#xD;
&#xD;
          -  Those who have a drug abuse history within one year prior to first administration of&#xD;
             investigational product or positive reaction on urine drug screening test.&#xD;
&#xD;
          -  Those who take barbiturate and related (causing induction or inhibition of metabolism)&#xD;
             drug within 1 month before the first administration of investigational product.&#xD;
&#xD;
          -  Those who received following drugs, which may affect results of clinical trial and&#xD;
             safety.&#xD;
&#xD;
               -  Ethical-the-counter (ETC) drugs or Over-the-counter (OTC) drugs within 10 days&#xD;
                  before the first administration of the investigational drug (especially&#xD;
                  Glecaprevir, Pibrentasvir).&#xD;
&#xD;
          -  Those who donated whole blood within 2 months or apheresis within 1 month or received&#xD;
             transfusion within 1 month.&#xD;
&#xD;
          -  Those who have history of hypersensitivity to active pharmaceutical ingredient or&#xD;
             Dihydropyridine or Aspirin, antibiotics etc.&#xD;
&#xD;
          -  Those who deemed to ineligible for participation of clinical trial,&#xD;
&#xD;
               -  Patient with hyperkalemia&#xD;
&#xD;
               -  Patients with hepatopathy&#xD;
&#xD;
               -  Patients with hereditary angioedema, ACE inhibitors or angiotensin II receptor&#xD;
                  antagonists who have a history of angioedema&#xD;
&#xD;
               -  Primary hyperaldosteronism&#xD;
&#xD;
               -  Patients with aortic valve stenosis, mitral (valve) stenosis, hypertrophic&#xD;
                  obstructive cardiomyopathy&#xD;
&#xD;
               -  Patients with ischemic heart disease, ischemic cardiovascular disease,&#xD;
                  cerebrovascular disease&#xD;
&#xD;
               -  Patients with Intravascular volume depletion&#xD;
&#xD;
               -  Patients with diabetes or kidney failure&#xD;
&#xD;
               -  Patients with renal artery stenosis&#xD;
&#xD;
               -  Patients with muscle disease&#xD;
&#xD;
               -  Patients with Hypothyroidism&#xD;
&#xD;
               -  Patients with a history of muscle toxicity when using statins or fibrates&#xD;
&#xD;
               -  Patients who have recently had a kidney transplant&#xD;
&#xD;
               -  Patients with history of shock&#xD;
&#xD;
          -  Those who have genetic problems such as galactose intolerance, Lapp lactose deficiency&#xD;
             or glucose-galactose malabsorption.&#xD;
&#xD;
          -  Those who took caffeine or grapefruit within 3 months(5 cups/day) (before the first&#xD;
             administration of investigational product) and can't stop taking caffeine or&#xD;
             grapefruit until the end of clinical trial.&#xD;
&#xD;
          -  Those who can't eat standard meal during hospitalization.&#xD;
&#xD;
          -  Those who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Those who are deemed to ineligible for participation of clinical trial by&#xD;
             investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Jang Hee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungnam National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hong Jang Hee, M.D.</last_name>
    <phone>+82-42-280-6940</phone>
    <email>boniii@cnu.ac.kr</email>
  </overall_contact>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 11, 2020</study_first_submitted>
  <study_first_submitted_qc>November 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CKD-333</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

